now thats a good result - i was looking for a Q4 of $4m3, $53m...

  1. 494 Posts.
    now thats a good result - i was looking for a Q4 of $4m3, $53m is very strong. On full year growth - net sales were up 142% on FY12.

    did they say anything on market share or rebating?
    If total prescription sales are slowing like MacBank say they are - Lilly must be either taking market share or reducing the rebates for Axiron....

    Would be nice to see ACR put out some further detail here!!!!
    after all - they do need to justify those high salaries somehow (when Lilly is doing all the hard work selling) :-)
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.9¢
Change
0.001(2.78%)
Mkt cap ! $7.543M
Open High Low Value Volume
1.8¢ 1.9¢ 1.8¢ $3.047K 167.8K

Buyers (Bids)

No. Vol. Price($)
2 175000 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 554258 3
View Market Depth
Last trade - 11.22am 24/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.